2023-508281-15-00招募中1 期
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 18
- 主要终点
- Dose Escalation Phase: The determination of the RP2D of ABBV-151 as monotherapy and in combination with budigalimab
研究概览
简要总结
Dose Escalation Phase: To determine the RP2D of ABBV-151 administered as monotherapy and in combination with budigalimab. Dose Expansion Phase: To assess the preliminary efficacy, based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, with the measured objective response rate (ORR) of ABBV-151 in combination with budigalimab in selected tumor types.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •For Dose Escalation only: Subjects with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, subjects who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case-by-case basis, after discussion with and agreement from the sponsor.
- •Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
- •For Dose Expansion only: Subjects must have measurable disease per RECIST1.1
- •For Dose Expansion only: All subjects with MSS-CRC, HCC, or pancreatic adenocarcinoma must not have had prior treatment with a PD-1/PDL-1 antagonist in any line of therapy
- •Subject has adequate bone marrow, renal, hepatic, and coagulation function.
- •For Dose Escalation only: Subjects with pancreatic adenocarcinoma, urothelial cancer, Hepatocellular carcinoma (HCC), or Head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion.
- •For Dose Expansion only subjects must meet criteria specific to the type of cancer: Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (including gemcitabine monotherapy or in combination with other agents, FOLFIRINOX [or another regimen including both 5-fluorouracil and oxaliplatin], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or metastatic setting. Progression on more than 1 prior systemic therapy is not allowed in this cohort. If the therapy was used in an adjuvant setting, disease progression must have occurred within 6 months of completing adjuvant therapy.
- •For Dose Expansion only subjects must meet criteria specific to the type of cancer: Urothelial cancer of the bladder and urinary tract and must have progressed following treatment with a platinum-based regimen (administered in any line of therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).
- •For Dose Expansion only subjects must meet criteria specific to the type of cancer: HCC and must have disease progression during or after 1 prior line of systemic therapy. Progression on more than 1 prior systemic therapy is not allowed in this cohort.
- •For Dose Expansion only subjects must meet criteria specific to the type of cancer: HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or antiPDL1 therapy).
- •For Dose Expansion only subjects must meet criteria specific to the type of cancer: MSS-CRC subjects with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by PCR/NGS or IHC, respectively) who have received prior fluorouracil-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or without VEGF and/or EGFR targeted agents).
- •Subjects with progression on or after more than 2 prior systemic therapies in the metastatic setting will not be eligible for this cohort - NSCLC subjects with histologically or cytologically confirmed advanced or metastatic NSCLC who have received 1 prior line of chemotherapy and 1 prior anti-PD- (L)1 antibody, administered either concurrently or sequentially in the metastatic setting. Subjects who have progressed on more than 1 line of chemotherapy in the metastatic setting and/or prior anti-PD (L)1 in the metastatic setting and with known EGFR mutations or ALK gene rearrangements will not be eligible.
排除标准
- •Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug.
- •Subject has unresolved AEs > Grade 1 from prior anticancer therapy except for alopecia.
- •Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis.
- •Has a known uncontrolled metastases to the central nervous system (with certain exceptions).
- •Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.
结局指标
主要结局
Dose Escalation Phase: The determination of the RP2D of ABBV-151 as monotherapy and in combination with budigalimab
Dose Escalation Phase: The determination of the RP2D of ABBV-151 as monotherapy and in combination with budigalimab
Dose Expansion Phase: Objective Response Rate of CR or PR
Dose Expansion Phase: Objective Response Rate of CR or PR
次要结局
- Dose Escalation Phase: Assessment of AEs, serious AEs (SAEs), laboratory parameters, vital signs, electrocardiogram (ECG) results, PK measurements, and antidrug antibody (ADA) measurements.
- Dose Expansion Phase: Duration of response (DOR)
- Dose Expansion Phase: Progression-free survival (PFS)
- Dose Expansion Phase: Assessment of AEs, SAEs, laboratory parameters, vital signs, ECG results, PK, and ADA measurements
研究者
Aleksandra Jankielewicz
Scientific
AbbVie Deutschland GmbH & Co. KG
研究点 (18)
Loading locations...
相似试验
已完成
1 期
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors2024-513625-23-00AbbVie Deutschland GmbH & Co. KG168
终止
1 期
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerColorectal CarcinomaNon-small Cell Lung CancerGlioblastoma MultiformeNCT02365662AbbVie46
已完成
1 期
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTumor, SolidNCT04840394Eikon Therapeutics1
终止
1 期
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT01402440Novartis Pharmaceuticals15
招募中
1 期
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsSolid TumorNCT06384807Biohaven Therapeutics Ltd.500